Report Highlights

U.S. Patellar Tendinitis Market Overview

The U.S. patellar tendinitis market reached USD 890 million in 2024 and is projected to reach USD 1.6 billion by 2032 at a 7.6% CAGR, driven by the growing sports and physically active adult population, increasing recognition of patellar tendinopathy as a chronic condition requiring structured management rather than short-term symptomatic treatment, and the expanding therapeutic options — including PRP injection, high-volume injection, extracorporeal shockwave therapy, and emerging biologic approaches — that are creating new treatment categories with premium pricing above conventional physiotherapy and NSAID-based management. Patellar tendinitis — also termed patellar tendinopathy or jumper's knee — affects an estimated 14% of recreational athletes and 45% of elite jumping sports athletes, creating a large and commercially addressable patient population in a country where sports participation rates are high and sports medicine infrastructure is among the most developed globally.

The market spans a spectrum of management approaches whose commercial dynamics differ substantially. Conservative management — physical therapy, eccentric exercise programmes, activity modification, and NSAID therapy — accounts for the majority of episodes by treatment count but generates per-episode revenue below the specialist intervention segment. Injection-based management — PRP, corticosteroid, high-volume injection, prolotherapy — generates premium revenue per procedure and is growing faster than conservative management as the evidence base for injection approaches matures and sports medicine physician adoption expands. Surgical management — open patellar tendon debridement, arthroscopic procedures, and minimally invasive ultrasound-guided tenotomy — represents the high-complexity end of the market serving cases refractory to conservative and injection-based management, generating the highest per-episode revenue but representing a small fraction of total treatment episodes.

Growth Drivers for U.S. Patellar Tendinitis Market

Three demand drivers sustain the U.S. patellar tendinitis market's growth through 2032. The sports participation growth driver — where U.S. recreational sports participation including basketball, volleyball, soccer, and running is growing at above-population-growth rates as health consciousness and active lifestyle adoption expand — is creating incremental patellar tendinitis incidence that increases the total patient population requiring management. The shift from acute injury management to chronic tendinopathy recognition — where patients and clinicians are increasingly understanding patellar tendinitis as a chronic condition requiring sustained management rather than a self-limiting injury that resolves with rest — is extending the treatment duration per patient and increasing the total commercial value of each patellar tendinitis case. The premium-to-conservative treatment migration — where patients with chronic or recurrent patellar tendinitis who have not responded adequately to exercise and rest are actively seeking specialist injection and procedure-based management — is the highest-revenue-impact driver, as each patient migrating from conservative to specialist management generates 8–15× the per-episode commercial value.

Extracorporeal shockwave therapy adoption is creating a new premium treatment revenue category within patellar tendinitis management that did not exist at significant commercial scale a decade ago. FDA-cleared ESWT devices — including Storz Medical, Chattanooga, and Zimmer MedizinSysteme platforms — are being deployed in sports medicine clinics, physical therapy practices, and orthopaedic offices as a reimbursable treatment modality for chronic tendinopathies including patellar tendinitis. The current procedural terminology code for focused extracorporeal shock wave therapy (CPT 28890) and the emerging reimbursement environment for radial pressure wave therapy are creating a billable procedure revenue category that is converting patellar tendinitis from a physiotherapy-dominated, low-per-visit-revenue condition to a specialist procedure category with per-session revenue of USD 150–450 that transforms the commercial economics of patellar tendinitis management for sports medicine and orthopaedic practices.

Regulatory and Reimbursement Environment

The U.S. patellar tendinitis treatment market's regulatory and reimbursement framework significantly shapes the commercial viability of different management approaches. Physical therapy for patellar tendinitis is broadly covered by Medicare and commercial health insurance under PT evaluation and treatment CPT codes, with coverage typically limited to a defined number of visits per year with medical necessity documentation requirements. Corticosteroid injection for patellar tendinitis is covered by most commercial payers but its use is increasingly discouraged in clinical guidelines due to evidence of tendon weakening and increased re-rupture risk — limiting the commercial growth of corticosteroid injection as patellar tendinitis management increasingly shifts toward PRP and biologic approaches. PRP injection for patellar tendinitis is classified as experimental by most major U.S. commercial payers — including Aetna, Cigna, and United Healthcare — resulting in cash-pay market dynamics where PRP is priced at USD 400–1,200 per injection without insurance coverage, limiting patient access but sustaining premium pricing for the treatments that patients elect to pursue at cash-pay rates.

Extracorporeal shockwave therapy reimbursement for patellar tendinitis is inconsistent across payers — Medicare covers focused ESWT for plantar fasciitis under CPT 28890 but does not have an equivalent approved coverage determination for patellar tendinitis, and commercial payer coverage varies significantly by plan and geographic market. The inconsistent ESWT reimbursement creates a market where ESWT for patellar tendinitis is offered in some markets as a cash-pay procedure and in others as a covered service depending on the payer mix of the treating practice — creating geographic revenue variability that complicates national market projections and investment planning for ESWT device manufacturers. Emerging biologic injection approaches — including platelet lysate, growth factor concentrates, and autologous tenocyte injection — face similar cash-pay market dynamics as PRP, with clinical evidence generation and payer coverage advocacy required before mainstream reimbursement can be expected for these next-generation injection approaches.

Market Opportunities in U.S. Patellar Tendinitis Market

The minimally invasive ultrasound-guided tenotomy opportunity — using devices such as the Tenex Health TX system or the Tenjet microtendon debridement system to percutaneously debride tendon pathology under real-time ultrasound guidance — represents a procedure-based revenue opportunity that converts refractory patellar tendinitis from a surgical candidate condition to a minimally invasive outpatient procedure with same-day return to activity and significantly lower complication risk than open surgical debridement. Tenex Health's TENEX HEALTH TX procedure has achieved CPT code reimbursement for percutaneous tenotomy (CPT 27680 modified) in several commercial payer markets, converting the procedure from a cash-pay premium offering to a reimbursed specialist procedure that sports medicine physicians can bill within conventional outpatient clinic practice. The ultrasound-guided minimally invasive tenotomy market for tendinopathies is growing at approximately 18% annually as sports medicine physician training in musculoskeletal ultrasound expands and device manufacturers invest in procedure training programmes that increase the qualified provider base.

The digital therapeutics and remote monitoring opportunity for patellar tendinitis management is creating a new commercial segment at the intersection of digital health, sports medicine, and musculoskeletal physical therapy. Digital exercise therapy platforms — including Hinge Health, Sword Health, and Kaia Health — are providing patellar tendinitis-specific exercise programmes with motion sensor feedback, telemedicine physical therapist supervision, and outcome tracking that improve programme adherence relative to home exercise prescription alone. These digital musculoskeletal therapy platforms are achieving commercial traction through employer health benefit and health plan contracts that provide covered access to the digital exercise programmes for employees and plan members with musculoskeletal conditions — creating a managed care revenue model for patellar tendinitis conservative management that generates per-member-per-month recurring revenue rather than fee-for-service episode payment.

Market at a Glance

Leading Market Participants

• Arthrex
• Biomet Sports Medicine (Zimmer Biomet)
• Storz Medical
• Tenex Health
• Hinge Health
• Chattanooga (DJO Global)
• Breg
• BSN Medical (Essity)
• EmCyte Corporation
• Harvest Technologies (Terumo BCT)

Competitive Outlook for U.S. Patellar Tendinitis Market

The U.S. patellar tendinitis market will reach USD 1.6 billion by 2032, with the treatment landscape continuing to migrate toward specialist injection and minimally invasive procedure-based management as the evidence base for these approaches matures and physician adoption expands through sports medicine training programme integration. PRP reimbursement coverage advocacy — driven by the growing systematic review evidence base and the active engagement of sports medicine societies in payer evidence reviews — is the most commercially significant near-term development, as PRP coverage by major commercial payers would expand the PRP-eligible patient population from cash-pay self-selectors to the full commercially insured population with patellar tendinitis diagnosis, multiplying accessible market volume several-fold. The digital therapeutics platforms' growth will capture an increasing share of conservative management revenue as employer health benefits and health plan contracting provide scale distribution that individual physical therapy practices cannot match, consolidating the conservative management segment around digital platform operators while leaving specialist injection and procedure management in the hands of sports medicine and orthopaedic physician practices.

The most commercially attractive position in the 2032 U.S. patellar tendinitis market will be minimally invasive ultrasound-guided tenotomy device manufacturers with established CPT reimbursement and trained sports medicine physician networks — providing a procedure-based revenue model that generates device sale revenue, training programme fees, and per-procedure supply revenue without dependence on the cash-pay market economics that currently constrain the PRP and biologic injection segments. Manufacturers who achieve CPT reimbursement for ultrasound-guided percutaneous tendon procedures in the most prevalent payer markets before 2027 will establish the billing infrastructure and physician adoption base that creates compounding revenue growth through 2032 as procedure awareness and physician training reach the critical mass that converts patellar tendinitis from an under-treated chronic condition to a well-defined treatment pathway with premium specialist procedure revenue at scale.